San Francisco, CA, United States of America

Mark J Selby

This inventor holds 89 USPTO granted patents and 44 published patent applications, plus 8 CIPO patents and 20 EPO patents, primarily in Monoclonal Antibodies (CPC class C07K2317-21). Top assignees: Bristol-Myers Squibb Compnay, E. R. Squibb Sons, Inc., Chiron Corporation. Active years: 1999-2026.

USPTO Granted Patents = 89 (Patent Applications = 44)

% Patents Active = 93.3

CIPO Patents = 8 (Patent Applications = 13)

EPO Patents = 20 (Patent Applications = 39)

Average Co-Inventor Count = 5.1

ph-index = 18

Forward Citations = 3,061(Granted Patents)

Forward Citations (Not Self Cited) = 2,714(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Emeryville, CA (US) (2008)
San Franciso, CA (US) (2008)
San Francisco, CA (US) (1999 - 2023)

Company Filing History:

30 out of 3,736

Bristol-Myers Squibb Compnay

patents

23 out of 1,624

E. R. Squibb Sons, Inc.

Novartis Vaccines & Diagnostics, Gmbh

Ono Pharmaceutical Co., Ltd.

patents

7. 2 out of 77

Five Prime Therapeutics, Inc.

9. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

TIM3

LAG-3

GITR

PD-1

ICOS

Cancer Diagnostics

Tumor Treatment

Human Antibodies

Immunotherapy

Antibody Variants

Tumor Necrosis Factor

89 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747296 - ANTI-CCR8 ANTIBODIES FOR TREATING CANCER (2026-09-29),

2. 12622954 - ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF (2026-05-12),

3. 12435136 - Antibodies binding to ILT4 (2025-10-07),

4. 12312403 - Antibodies against TIM3 and uses thereof (2025-05-27),

5. 12227575 - Combination of TIM-4 antagonist and PD-1 antagonist and methods of use (2025-02-18),

6. 12129297 - Antibodies against TIM3 and uses thereof (2024-10-29),

7. 12110337 - Anti-CD27 antibodies and uses thereof (2024-10-08),

8. 11802162 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof (2023-10-31),

9. 11591392 - Antibodies against TIM3 and uses thereof (2023-02-28),

10. 11530267 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-12-20),

11. 11529399 - Anti-ICOS agonist antibodies and uses thereof (2022-12-20),

12. 11512130 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-11-29),

13. 11408889 - Anti-GITR antibodies for cancer diagnostics (2022-08-09),

14. 11401328 - Antibodies binding to ILT4 (2022-08-02),

15. 11306143 - Combination of TIM-4 antagonist and PD-1 antagonist and methods of use (2022-04-19),

Title: Mark J. Selby: Pioneering Innovations in Cancer Treatment

Introduction

Mark J. Selby is a distinguished inventor based in San Francisco, CA, recognized for his substantial contributions to the field of cancer therapy. With an impressive portfolio of 85 patents, Selby has consistently been at the forefront of medical innovations that aim to improve patient outcomes in oncology.

Latest Patents

Among his most recent patents are significant advancements in the treatment of cancer. One such patent is for the combination of TIM-4 antagonist and PD-1 antagonist, providing methods and compositions for effectively treating cancer using these agents. This innovation highlights his focus on harnessing the immune system to fight cancer.

Additionally, Selby has developed antibodies against TIM3, detailing the uses of these antibodies in therapeutic applications for cancer treatment. His innovations extend to the creation of cells that produce these antibodies, along with the associated polynucleotides and vectors necessary for their production, showcasing his comprehensive approach to biomedical research.

Career Highlights

Throughout his career, Selby has made significant contributions while working with notable companies such as Bristol-Myers Squibb Company and E.R. Squibb & Sons, L.L.C. His work at these leading pharmaceutical firms has helped shape the landscape of cancer treatment and biotherapeutics.

Collaborations

Mark Selby has collaborated with esteemed colleagues in the industry, including Alan J. Korman and Mohan Srinivasan. These partnerships have further enhanced his research and innovation efforts, leading to the development of cutting-edge therapies that benefit patients worldwide.

Conclusion

Mark J. Selby stands out as a prominent inventor in the realm of cancer research, with his extensive patent portfolio reflecting his dedication to medical advancements. His groundbreaking work in combining immune therapies and developing novel antibodies serves as an inspiration for future innovations in the fight against cancer.